b16-f10  (ATCC)

Journal: Bioactive Materials

Article Title: “Artificial platelet injection system”: a plug-and-play platelet-based lysosome-targeting chimera for targeted protein degradation

doi: 10.1016/j.bioactmat.2026.01.011

Figure Lengend Snippet: │ PD-L1 degradation efficacy in vitro and in vivo by PLT-TACs in B16F10 cells. A , Western blot analysis of PD-L1 in IFN-γ pre-treated B16F10 cells after treated with saline, PLT-anti-PD-L1, PLT-TAC l , PLT-TAC m or PLT-TAC h (at an equivalent amount of 5 μM) for 36 h (n = 3 biologically independent samples). B , Mean fluorescence intensity of levels of surface PD-L1 in IFN-γ pre-treated B16F10 after treated with saline, PLT-anti-PD-L1, PLT-TAC l , PLT-TAC m or PLT-TAC h , measured by FCM (at an equivalent amount of 5 μM) for 36 h (n = 3 biologically independent samples). C , Schematic schedule of the treatment and evaluation in C57BL/6 mice with B16F10 homografting tumor model. D , Tumor growth curves, E , tumor weights, F , images of dissected tumors, G , survival curves from treatment groups (saline, PLT-anti-PD-L1, PLT-TAC l , PLT-TAC m or PLT-TAC h ) at a dosage of 5 mg/kg (n = 6 biologically independent samples). H , Immunohistochemical images of PD-L1 in dissected B16F10 tumors after treatment. I , Mean fluorescence intensity of PD-L1 in CD45-negative tumor cells from dissected tumors after treatment (n = 4 biologically independent samples). Data are presented as mean ± SD. p values were determined by one-way ANOVA test. ns, no significance; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

Article Snippet: Breast tumor cell line 4T1 and melanoma tumor cell line B16F10 were purchased from the American Type Culture Collection (ATCC), and cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin.

Techniques: In Vitro, In Vivo, Western Blot, Saline, Fluorescence, Immunohistochemical staining